Drug Trial Radar · NCT01469039
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Jan 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
623
Actual
Start
Dec 2011
Primary completion
Jan 2014
Study completion Mar 2014
Sponsor
- Lead sponsor
- Alkermes, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 10, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.
Conditions
- Schizophrenia
Interventions
ALKS 9072Drug
Intramuscular (IM) injection, 441 mg or 882 mg given monthly
PlaceboDrug
Placebo for IM injection, given monthly
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total ScoreTime frame: Data collected from baseline to day 85
Locations
84 sites in 8 countries. Site status is shown where the registry gives one.
Alkermes Investigational Site
Little Rock, Arkansas
Alkermes Investigational Site
Little Rock, Arkansas
Alkermes Investigational Site
Springdale, Arkansas
Alkermes Investigational Site
Cerritos, California
Alkermes Investigational Site
Garden Grove, California
Alkermes Investigational Site
La Habra, California
Alkermes Investigational Site
Oakland, California
Alkermes Investigational Site
Oceanside, California
Alkermes Investigational Site
Orange, California
Alkermes Investigational Site
San Diego, California
Alkermes Investigational Site
Washington D.C., District of Columbia
Alkermes Investigational Site
Fort Lauderdale, Florida
Alkermes Investigational site
Leesburg, Florida
Alkermes Investigational Site
Atlanta, Georgia
Alkermes Investigational Site
Chicago, Illinois
Alkermes Investigational Site
Hoffman Estates, Illinois
Alkermes Investigational Site
Overland Park, Kansas
Alkermes Investigational Site
Rockville, Maryland
Alkermes Investigational Site
Creve Coeur, Missouri
Alkermes Investigational Site
St Louis, Missouri
Alkermes Investigational Site
Philadelphia, Pennsylvania
Alkermes Investigational Site
Charleston, South Carolina
Alkermes Investigational Site
Austin, Texas
Alkermes Investigational Site
Austin, Texas
Alkermes Investigational Site
Dallas, Texas
Alkermes Investigational Site
Dallas, Texas
Alkermes Investigational Site
Burgas, Bulgaria
Alkermes Investigational Site
Kazanlak, Bulgaria
Alkermes Investigational Site
Novi Iskar, Bulgaria
Alkermes Investigational Site
Pazardzhik, Bulgaria
Alkermes Investigational Site
Pleven, Bulgaria
Alkermes Investigational Site
Plovdiv, Bulgaria
Alkermes Investigational Site
Radnevo, Bulgaria
Alkermes Investigational Site
Rousse, Bulgaria
Alkermes Investigational Site
Sofia, Bulgaria
Alkermes Investigational Site
Stara Zagora, Bulgaria
Alkermes Investigational Site
Targovishte, Bulgaria
Alkermes Investigational Site
Veliko Tarnovo, Bulgaria
Alkermes Investigational Site
Vratsa, Bulgaria
Alkermes Investigational Site
Cheras, Malaysia
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.